author-photo

Giulia Baciarello

University of Paris-Sud

33

Papers

387

Citations

Citation Trend

Filter By

Papers (20) Sort By

Journal Conference Others

Redefining Cancer Of Unknown Primary: Is Precision Medicine Really Shifting The Paradigm ?

2021 Cancer Treatment Reviews
Show All
- Source
- Cite
- Save
Citations (2)
Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?

2021 Therapeutic Advances in Medical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?: Authors

2020 Critical Reviews in Oncology Hematology
Show All
- Source
- Cite
- Save
Citations (7)
614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Association of the Lung Immune Prognostic Index with outcome in patients with metastatic urothelial cancer treated with immune checkpoint inhibitor.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

2020
Show All
- Source
- Cite
- Save
Citations (50)
Semi-ResMass Study: Residual masses after salvage chemotherapy in men with pure seminoma—A multicenter retrospective analysis.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
788P Urachal carcinoma: Large retrospective multicentric GETUG-AFU study

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (111)